CELLECTIS - ADR (CLLS:NASDAQ)
$3.63 0 (0%)
Analysed CELLECTIS - ADR (CLLS:NASDAQ) News Sources
Cellectis Reports Financial Results for the First Quarter 2026
11-05-2026
yahoo.com
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
12-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Decline Sharply in Tuesday Trading
12-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Tracking Higher in Thursday Trading
14-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Down Sharply in Friday Trading
15-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
19-05-2026
yahoo.com
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
20-05-2026
yahoo.com
[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
21-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
28-05-2026
yahoo.com
Barclays initiates oncology-focused biotechs with positive outlook
28-05-2026
yahoo.com
What is the current price of CELLECTIS - ADR (CLLS:NASDAQ)?
The current price of CELLECTIS - ADR (CLLS:NASDAQ) is $3.63.
CELLECTIS - ADR (CLLS:NASDAQ) absolute price change since previous trading day?
The absolute price change of CELLECTIS - ADR (CLLS:NASDAQ) since the previous trading day is $0.
CELLECTIS - ADR (CLLS:NASDAQ) percentage price change since previous trading day?
The percentage price change of CELLECTIS - ADR (CLLS:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for CELLECTIS - ADR (CLLS:NASDAQ)?
The most recent average sentiment score for CELLECTIS - ADR (CLLS:NASDAQ) is 37 out of 100.
What is the most recent average sentiment for CELLECTIS - ADR (CLLS:NASDAQ)?
The most recent sentiment for CELLECTIS - ADR (CLLS:NASDAQ) is .
SEC-8K** Filing Available For CELLECTIS - ADR (CLLS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.